Filing identity and reporting period
The supplied filing text is MEI Pharma, Inc.’s unaudited Form 10-Q for the quarter and nine months ended March 31, 2014—not a Lite Strategy, Inc. filing for 2012 Q3 as stated in the request metadata. The company describes itself as a development-stage oncology business. Amounts below are in U.S. dollars, generally in thousands, except per-share data.
Financial results and position
- Revenue: No revenue is reported; operations consist of research and development and general and administrative expenses.
- Quarterly results: For the three months ended March 31, 2014, net loss was $7.387 million, compared with $2.753 million in the prior-year quarter. Operating expenses were $7.406 million, including $5.415 million of R&D and $1.991 million of G&A. Basic and diluted loss per share was $0.34, versus $0.18.
- Nine-month results: Net loss was $18.607 million, compared with $7.971 million for the nine months ended March 31, 2013. Operating expenses were $18.669 million: R&D of $12.918 million and G&A of $5.751 million. Loss per share was $0.95, versus $1.00.
- Cash flow: Nine-month operating cash use was $13.601 million, compared with $7.278 million a year earlier. Investing activities used $35.028 million, primarily for purchases of short-term U.S. government securities. Financing provided $32.726 million, principally from an October 2013 stock offering.
- Liquidity and debt: At March 31, 2014, cash and cash equivalents were $19.670 million and short-term investments were $35.007 million, totaling $54.677 million. Current liabilities were $3.518 million; the balance sheet reports no debt. Accumulated development-stage deficit was $114.904 million.
- Margins: Not meaningful based on the filing’s lack of reported revenue.
Changes versus prior comparable periods
Quarterly net loss increased by $4.634 million year over year; nine-month net loss increased by $10.636 million. Management attributed higher R&D costs to Pracinostat manufacturing and Phase II trials, ME-344 manufacturing and clinical work, and PWT143 preclinical work. G&A also rose, including increased salaries and share-based compensation. Nine-month share-based compensation increased to $3.534 million from $0.766 million. Cash and short-term investments rose from $35.573 million at June 30, 2013 to $54.677 million at March 31, 2014, reflecting financing proceeds and investment of cash in short-term securities.
Outlook, risks, and notable items
- Management said existing cash, cash equivalents and short-term investments were expected to fund operations through calendar 2015, while warning that changes in development plans or expenses could affect runway. The company expected to seek additional financing or strategic partnerships at some point.
- Pracinostat was in three Phase II trials. Management anticipated completion of enrollment in its placebo-controlled MDS trial in Q3 2014 and data in Q1 2015; preliminary data from two other Phase II trials were anticipated in December 2014.
- ME-344’s Phase Ib combination trial began in May 2014, after the reporting date. The company expected to complete preclinical work supporting a PWT143 IND filing by the end of calendar 2014.
- The company reported accumulated losses and expected continued operating losses and negative operating cash flows. Key risks include clinical trial failure or delay, regulatory uncertainty, financing needs, competition, manufacturing costs, and intellectual-property risks.
- Potential obligations include S*Bio milestones and earnouts of up to $75.2 million tied to specified regulatory and sales milestones; no amount was accrued at March 31, 2014. CyDex license milestones and royalties may also be payable; no potential future payment was accrued. Clinical and consulting contracts are terminable but require reimbursement for costs incurred.
- In October 2013, MEI Pharma sold 4.375 million common shares at $8.00 per share, receiving $32.7 million net. Shares outstanding were 21,607,234 at March 31, 2014; the filing reports 21,607,296 as of May 7, 2014.
- Management concluded disclosure controls were effective and reported no material change in internal control over financial reporting during the quarter.
Important facts for investors to verify
- Confirm the intended company and period: the source is MEI Pharma’s 2014 Q3 Form 10-Q, inconsistent with the request metadata.
- Assess whether the stated cash runway through calendar 2015 remains adequate against clinical-development spending and the possibility of additional financing.
- Track trial enrollment, timing, efficacy and safety updates for Pracinostat and ME-344, and progress toward the PWT143 IND filing.
- Review potential dilution from outstanding warrants, options and restricted stock units, as well as future equity financing needs.
- Evaluate contingent S*Bio and CyDex obligations and the clinical, regulatory, intellectual-property and execution risks described in the filing.